,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2012-03-12 02:00:00,"Medical technology has been stalled in a quagmire of regulation, lowered usage and a more tight-fisted health insurance environment, but Analyst and Managing Director Joanne Wuensch of BMO Capital Markets has identified a few ground-breaking technologies that will drive increasing cash flows in particular companies.",0.6306893229484558,0.03656616061925888,0.3327445983886719,positive,0.5941231846809387
1,2012-03-12 02:00:00,"In this exclusive interview with The Life Sciences Report , Wuensch delivers the names that will provide essential diversification while they return growth for investors.",0.4424888789653778,0.009622297249734402,0.5478888750076294,neutral,0.43286657333374023
2,2012-03-12 02:00:00,"The Life Sciences Report: Medical technology (medtech) stocks have taken a breather since the beginning of February, but they had quite a run-up between mid-December and early February.",0.11247895658016205,0.7174316048622131,0.1700894832611084,negative,-0.6049526333808899
3,2012-03-12 02:00:00,I'm wondering if this has been a response to an improving economy or does it mean medtech is in a secular uptrend?,0.29869866371154785,0.226723313331604,0.47457802295684814,neutral,0.07197535037994385
4,2012-03-12 02:00:00,Joanne Wuensch: I think that the group was generally oversold in Q411.,0.025637632235884666,0.9432579278945923,0.03110441192984581,negative,-0.9176203012466431
5,2012-03-12 02:00:00,Multiples were meaningfully compressed.,0.029406633228063583,0.5264089703559875,0.44418445229530334,negative,-0.49700233340263367
6,2012-03-12 02:00:00,"There was some positive commentary about increased or improving utilization from management at Johnson & Johnson (JNJ:NYSE) on its Q4 call, and from one of the lab companies.",0.9464499950408936,0.018910838291049004,0.03463916853070259,positive,0.9275391697883606
7,2012-03-12 02:00:00,It then became sort of a self-fulfilling prophecy whereby depressed stocks reacted and we saw a lot of short covering and a lot of money chasing money.,0.06399713456630707,0.03887220099568367,0.8971306681632996,neutral,0.025124933570623398
8,2012-03-12 02:00:00,"So, we had some very nice price performance in the first eight weeks of the year.",0.8388321995735168,0.01886758580803871,0.14230024814605713,positive,0.819964587688446
9,2012-03-12 02:00:00,"TLSR: So, if medtech is not in a secular uptrend, is this a response to an improving economy?",0.5859638452529907,0.022285109385848045,0.3917510509490967,positive,0.5636787414550781
10,2012-03-12 02:00:00,JW: I think that in many ways the fundamentals are no different today than they were in November.,0.12117904424667358,0.16734196245670319,0.7114790081977844,neutral,-0.0461629182100296
11,2012-03-12 02:00:00,The only thing that has changed is that multiples have become a little bit more normalized and not as depressed.,0.24558670818805695,0.025029273703694344,0.7293840050697327,neutral,0.22055743634700775
12,2012-03-12 02:00:00,"And, as we look at 2012 guidance, a lot of these companies are not assuming a recovery in the second half of the year, which means that estimates are largely achievable for 2012.",0.06664695590734482,0.1982044130563736,0.7351486682891846,neutral,-0.13155746459960938
13,2012-03-12 02:00:00,And that's a relief.,0.7675743103027344,0.02684529684484005,0.20558030903339386,positive,0.740729033946991
14,2012-03-12 02:00:00,TLSR: You've written rather extensively about more rigorous U.S. Food and Drug Administration (FDA) regulation around medical device development.,0.08288780599832535,0.01338798739016056,0.9037241339683533,neutral,0.06949982047080994
15,2012-03-12 02:00:00,It has slowed approvals.,0.017480546608567238,0.9612151384353638,0.02130436897277832,negative,-0.9437345862388611
16,2012-03-12 02:00:00,How significant is this issue?,0.030718985944986343,0.043004006147384644,0.9262769818305969,neutral,-0.0122850202023983
17,2012-03-12 02:00:00,"JW: Well, it's significant because this industry is driven by technology innovation.",0.4399612843990326,0.009008659049868584,0.5510300397872925,neutral,0.43095263838768005
18,2012-03-12 02:00:00,"So, whether you slow down innovation by slowing down approvals or by increasing hurdles required to bring new technology to market, it is more difficult.",0.12957130372524261,0.04867091774940491,0.8217577934265137,neutral,0.08090038597583771
19,2012-03-12 02:00:00,We are seeing the need for clinical data for 510(k) premarket notifications that were previously accomplished without clinical studies.,0.17178639769554138,0.013456201180815697,0.8147573471069336,neutral,0.15833020210266113
20,2012-03-12 02:00:00,"[Note: Under the 510(k) process of the Federal Food, Drug and Cosmetic Act, if a device is substantially equivalent in safety and its activity or effectiveness, clinical trials are not required].",0.02364625595510006,0.014019819907844067,0.9623339176177979,neutral,0.009626436047255993
21,2012-03-12 02:00:00,"Sometimes companies run a clinical trial according to specifications from the FDA, and then the FDA sort of sits on the approval process until further notice.",0.013828595168888569,0.016989344730973244,0.9691820740699768,neutral,-0.003160749562084675
22,2012-03-12 02:00:00,We have also seen increased need for economic data from the FDA.,0.570369303226471,0.021723071113228798,0.4079076647758484,positive,0.5486462116241455
23,2012-03-12 02:00:00,TLSR: How much of this is attributable to increasing complexity in the medtech field?,0.047449205070734024,0.014649523422122002,0.9379013180732727,neutral,0.03279968351125717
24,2012-03-12 02:00:00,JW: Some of it is increasing complexity.,0.048850469291210175,0.27569371461868286,0.6754557490348816,neutral,-0.2268432378768921
25,2012-03-12 02:00:00,"Some of it has to do with some very high profile problems, such as concerns about metal-on-metal hips, things like that.",0.016426581889390945,0.09075237065553665,0.8928210139274597,neutral,-0.07432578504085541
26,2012-03-12 02:00:00,"A new brand of hips was approved by FDA with limited clinical data, and it was a little bit of a black eye on the FDA.",0.048364877700805664,0.7524265646934509,0.1992085725069046,negative,-0.7040616869926453
27,2012-03-12 02:00:00,TLSR: What are the other headwind issues you are seeing?,0.01853635534644127,0.1254732310771942,0.855990469455719,neutral,-0.10693687200546265
28,2012-03-12 02:00:00,"JW: Well, the most basic one is decreased utilization, and that is somewhat driven by the economy.",0.02374161034822464,0.8734548687934875,0.10280357301235199,negative,-0.8497132658958435
29,2012-03-12 02:00:00,"Also, the delivery of healthcare has changed over the last 24 months with the advent of higher co-payments and annual deductibles.",0.5028190612792969,0.030966566875576973,0.4662143886089325,positive,0.47185248136520386
30,2012-03-12 02:00:00,"Overall, price pressure is higher.",0.5706638097763062,0.06703756004571915,0.3622986674308777,positive,0.5036262273788452
31,2012-03-12 02:00:00,Hospitals are more conscious of cost.,0.07953396439552307,0.026814280077815056,0.8936517238616943,neutral,0.052719682455062866
32,2012-03-12 02:00:00,Administrators have even changed the way products are stocked to save money.,0.0477784164249897,0.4856097996234894,0.4666118621826172,negative,-0.4378313720226288
33,2012-03-12 02:00:00,"Physicians who used to be independent are now working for hospitals, who are managing their expenses.",0.016633780673146248,0.03513937443494797,0.948226809501648,neutral,-0.01850559376180172
34,2012-03-12 02:00:00,"Also, payers are requiring more clinical data to reimburse for a product, and patients have to pay a higher percentage of the surgical and product cost.",0.03878288343548775,0.7064382433891296,0.25477880239486694,negative,-0.667655348777771
35,2012-03-12 02:00:00,All of these things have changed healthcare.,0.04527436941862106,0.09749865531921387,0.8572269678115845,neutral,-0.052224285900592804
36,2012-03-12 02:00:00,TLSR: I can't help but wonder if all of this additional FDA diligence going into development might help when going to Centers for Medicare & Medicaid Services ( CMS ) to request approval for reimbursement?,0.3329698443412781,0.01776505447924137,0.6492650508880615,neutral,0.31520479917526245
37,2012-03-12 02:00:00,"JW:In theory, if you have more economic data, it would help when going to CMS for reimbursement.",0.3320856988430023,0.01229515578597784,0.6556191444396973,neutral,0.3197905421257019
38,2012-03-12 02:00:00,TLSR: Are these extended approval times driving medtech companies to sell products in emerging and international markets?,0.7007718086242676,0.01848568581044674,0.2807425260543823,positive,0.6822861433029175
39,2012-03-12 02:00:00,"JW: Sadly, yes.",0.16804708540439606,0.44741150736808777,0.38454142212867737,negative,-0.2793644070625305
40,2012-03-12 02:00:00,"There's a push for product sales outside the United States because you don't have to go through the FDA hoops, and you don't have to go through the CMS gauntlet.",0.21994759142398834,0.00974877830594778,0.7703036069869995,neutral,0.21019881963729858
41,2012-03-12 02:00:00,There is also a push into emerging markets because they are largely untapped.,0.7476613521575928,0.017948975786566734,0.23438966274261475,positive,0.7297123670578003
42,2012-03-12 02:00:00,"It used to be that a company would get a product approved first in Europe, then here in the U.S. and then in Japan.",0.10853935778141022,0.00813337042927742,0.8833272457122803,neutral,0.1004059910774231
43,2012-03-12 02:00:00,There was zero discussion of emerging markets.,0.023125339299440384,0.017983870580792427,0.9588907957077026,neutral,0.005141468718647957
44,2012-03-12 02:00:00,"The amount of time between approvals from one region to another was one year, maybe two years, but not an extreme period.",0.03626415133476257,0.014210681430995464,0.9495252370834351,neutral,0.022053468972444534
45,2012-03-12 02:00:00,"Now you have products, like transcatheter heart valves (TCHV), that are approved in Europe four years before they're approved in the United States.",0.09668425470590591,0.0086443442851305,0.8946713805198669,neutral,0.08803991228342056
46,2012-03-12 02:00:00,"And, then there's another 18-month, maybe 24-month gap before it is approved in Japan.",0.05710750073194504,0.03917660191655159,0.9037159085273743,neutral,0.017930898815393448
47,2012-03-12 02:00:00,That's for a high technology product.,0.06275449693202972,0.007177670486271381,0.930067777633667,neutral,0.05557682737708092
48,2012-03-12 02:00:00,"Now, even for a lower technology product, companies are talking about emerging markets on every single conference call.",0.09684451669454575,0.02114008367061615,0.8820153474807739,neutral,0.0757044330239296
49,2012-03-12 02:00:00,Going into emerging markets may mean opening a manufacturing facility in China.,0.41659805178642273,0.010935246013104916,0.5724667310714722,neutral,0.40566280484199524
50,2012-03-12 02:00:00,"It may mean increasing your selling, general and administrative expense (SG&A) or redirecting your SG&A to hire feet on the street in those markets.",0.04091765359044075,0.019719405099749565,0.9393629431724548,neutral,0.021198248490691185
51,2012-03-12 02:00:00,"Or in a more subtle or direct way, a company might create a product that is particularly attuned to the emerging markets.",0.11552310734987259,0.008159765042364597,0.8763171434402466,neutral,0.10736334323883057
52,2012-03-12 02:00:00,TLSR: Can those data from markets outside the U.S. be used at the FDA?,0.016130099073052406,0.009868080727756023,0.9740018248558044,neutral,0.006262018345296383
53,2012-03-12 02:00:00,"JW: Well, can they be submitted?",0.029267488047480583,0.01267323363572359,0.9580592513084412,neutral,0.016594253480434418
54,2012-03-12 02:00:00,By all means submit it.,0.07371021807193756,0.007085254415869713,0.9192045331001282,neutral,0.0666249617934227
55,2012-03-12 02:00:00,"How much the FDA uses that to come to a conclusion on approvability is still, in my opinion, in question.",0.023233667016029358,0.013639711774885654,0.963126540184021,neutral,0.009593955241143703
56,2012-03-12 02:00:00,"If you run a U.S. clinical trial and you have data from outside the U.S., I don't know if it matters a hill of beans versus a U.S.-run clinical trial and making a decision toward approvability.",0.06591959297657013,0.05354307219386101,0.8805373311042786,neutral,0.012376520782709122
57,2012-03-12 02:00:00,TLSR: Does dramatic innovation exist in medtech now?,0.5426875948905945,0.014198394492268562,0.4431140124797821,positive,0.5284891724586487
58,2012-03-12 02:00:00,JW: It does.,0.297159880399704,0.019896745681762695,0.6829434037208557,neutral,0.2772631347179413
59,2012-03-12 02:00:00,I would say that TCHVs are a dramatic innovation.,0.6674374938011169,0.010562957264482975,0.32199957966804504,positive,0.6568745374679565
60,2012-03-12 02:00:00,I would argue that renal denervation is dramatic innovation.,0.3846858739852905,0.008586803451180458,0.6067273616790771,neutral,0.3760990798473358
61,2012-03-12 02:00:00,"Also, patent foramen ovale ( PFO ) closure type devices, abdominal aortic aneurysm (AAA) devices and neurovascular products still hold a wide-open opportunity.",0.68580162525177,0.012366640381515026,0.3018316924571991,positive,0.6734349727630615
62,2012-03-12 02:00:00,"So, I think there is dramatic innovation.",0.5603039860725403,0.011472463607788086,0.42822352051734924,positive,0.5488315224647522
63,2012-03-12 02:00:00,"There's less of it, but it still exists.",0.04681510105729103,0.03594950586557388,0.9172353744506836,neutral,0.010865595191717148
64,2012-03-12 02:00:00,"TLSR: What about cardiac rhythm management ( CRM ), implantable cardioverter defibrillators (ICDs) and coronary artery stents?",0.023215580731630325,0.007738589309155941,0.9690458178520203,neutral,0.015476991422474384
65,2012-03-12 02:00:00,Would they figure into an aging baby boomer investment theory?,0.08835776150226593,0.04947666823863983,0.8621655702590942,neutral,0.0388810932636261
66,2012-03-12 02:00:00,JW: They do figure into an aging baby boomer theory as well as hips and knees obviously.,0.048626288771629333,0.015887117013335228,0.9354865550994873,neutral,0.032739169895648956
67,2012-03-12 02:00:00,TLSR: Are you bullish on the cardiovascular segment?,0.08520881831645966,0.07152087241411209,0.8432703614234924,neutral,0.013687945902347565
68,2012-03-12 02:00:00,JW: I'm not bullish on ICDs and stents.,0.05778929591178894,0.3749157786369324,0.5672948956489563,neutral,-0.31712648272514343
69,2012-03-12 02:00:00,I'm largely favoring some of the diversified names.,0.05399470403790474,0.007185873109847307,0.9388194680213928,neutral,0.04680883139371872
70,2012-03-12 02:00:00,"I am bullish on two cardiology companies, Medtronic Inc. (MDT:NYSE) and Jude Medical Inc. (STJ:NYSE), but for different reasons.",0.07280514389276505,0.10805995017290115,0.8191348910331726,neutral,-0.03525480628013611
71,2012-03-12 02:00:00,I have them both rated Outperform.,0.1772259622812271,0.48020845651626587,0.3425655663013458,negative,-0.30298250913619995
72,2012-03-12 02:00:00,Medtronic is trading at a discount to the group's 12-13 times multiple.,0.051582641899585724,0.02691829204559326,0.9214990735054016,neutral,0.024664349853992462
73,2012-03-12 02:00:00,"Medtronic has had its problems, particularly in spine, but it's giving a nice dividend of almost 3%.",0.35840293765068054,0.1652839332818985,0.47631314396858215,neutral,0.19311900436878204
74,2012-03-12 02:00:00,"And, I suspect the relatively new CEO Omar Ishrak, who came from GE Healthcare Systems, a unit of the General Electric Company (GE:NYSE), will start to do some company portfolio management, and in the process we anticipate that the gap in the multiple differential will close.",0.41080528497695923,0.015394858084619045,0.5737998485565186,neutral,0.395410418510437
75,2012-03-12 02:00:00,TLSR: You had mentioned AAA as a growing technology.,0.5419535040855408,0.011973227374255657,0.4460732638835907,positive,0.5299803018569946
76,2012-03-12 02:00:00,Medtronic is in AAA.,0.05666237697005272,0.015677547082304955,0.9276600480079651,neutral,0.040984831750392914
77,2012-03-12 02:00:00,JW: It is absolutely.,0.22513285279273987,0.010097957216203213,0.7647691965103149,neutral,0.21503490209579468
78,2012-03-12 02:00:00,"It has some other higher technology pockets, renal denervation and TCHVs, and the company just launched a new drug-eluting stent in the U.S.",0.36340174078941345,0.008535215631127357,0.6280630826950073,neutral,0.35486653447151184
79,2012-03-12 02:00:00,"But there are some larger portions of its business, such as ICD and particularly its spine franchises, which have been declining.",0.017977815121412277,0.9105916619300842,0.07143054902553558,negative,-0.8926138281822205
80,2012-03-12 02:00:00,ICD has been bumping along the bottom.,0.1750480979681015,0.626977801322937,0.19797416031360626,negative,-0.4519296884536743
81,2012-03-12 02:00:00,"TLSR: These areas you just mentioned are catalysts for Medtronic, right?",0.09803806245326996,0.006232007872313261,0.8957298994064331,neutral,0.09180605411529541
82,2012-03-12 02:00:00,TLSR: Do you expect market-moving information this year?,0.01930667646229267,0.012352666817605495,0.9683406352996826,neutral,0.006954009644687176
83,2012-03-12 02:00:00,"JW: Well, the company hasn't had an analyst meeting in almost two years, but as I look out over the next 12 months, Medtronic will have its first analyst meeting under the new CEO in June of this year.",0.052360646426677704,0.012790474109351635,0.9348488450050354,neutral,0.039570171386003494
84,2012-03-12 02:00:00,"As he starts to unveil plans for how he's going to make his mark at the company, the stock should respond in kind.",0.36643853783607483,0.010694154538214207,0.6228673458099365,neutral,0.3557443916797638
85,2012-03-12 02:00:00,TLSR: You said you are bullish on St. Jude Medical.,0.16524021327495575,0.24811072647571564,0.5866490602493286,neutral,-0.08287051320075989
86,2012-03-12 02:00:00,"JW: Yes, this is a company that is still heavily devoted to the CRM market.",0.10505127161741257,0.0051925452426075935,0.8897562026977539,neutral,0.09985872358083725
87,2012-03-12 02:00:00,"But also similar to Medtronic, it is investing in the higher growth areas, such as atrial fibrillation, TCHVs, renal denervation and PFO closure devices.",0.1684681475162506,0.005527761299163103,0.826004147529602,neutral,0.1629403829574585
88,2012-03-12 02:00:00,"It has also been steadily taking share in the ICD market, and it received FDA approval in Q411 for a new quadripolar pacing lead, which allowed it to take some market share in Europe.",0.9383275508880615,0.01495811715722084,0.04671435058116913,positive,0.9233694076538086
89,2012-03-12 02:00:00,"There is a similar expectation here in the U.S.

TLSR: Can we talk about your other Outperform-rated companies?",0.0809018611907959,0.018334465101361275,0.9007636308670044,neutral,0.06256739795207977
90,2012-03-12 02:00:00,"JW: Sure, let's take them individually.",0.028000902384519577,0.008366256020963192,0.9636328220367432,neutral,0.01963464543223381
91,2012-03-12 02:00:00,Covidien Plc (COV:NYSE) was spun out from Tyco Healthcare Group LP about four years ago.,0.024545248597860336,0.014260890893638134,0.961193859577179,neutral,0.010284357704222202
92,2012-03-12 02:00:00,It has done a very good job of rearranging its architecture.,0.6349549293518066,0.011134956032037735,0.3539101183414459,positive,0.6238199472427368
93,2012-03-12 02:00:00,"It has sold off non-core businesses and actively invested in higher-growth business, and in the process it has expanded operating margins and generated a heck of a lot of cash.",0.9285233616828918,0.013478964567184448,0.05799759179353714,positive,0.9150444269180298
94,2012-03-12 02:00:00,"It's about to go through another transformation with the sale of its pharmaceutical franchise, and I expect that to happen in H113.",0.7366104125976562,0.011315722018480301,0.25207382440567017,positive,0.7252947092056274
95,2012-03-12 02:00:00,"It should end up as a company dedicated to medical devices, including some hospital supplies.",0.2501562237739563,0.006320860702544451,0.7435229420661926,neutral,0.24383535981178284
96,2012-03-12 02:00:00,I expect it to be a high single-digit revenue grower with a low- to mid-20%-type of operating margin.,0.24481096863746643,0.02522970177233219,0.7299593091011047,neutral,0.2195812612771988
97,2012-03-12 02:00:00,TLSR: Do you expect a catalyst this year to move the stock?,0.13092951476573944,0.02796124666929245,0.8411092758178711,neutral,0.10296826809644699
98,2012-03-12 02:00:00,"JW: As the company provides more information and details on the spinout of the pharmaceutical division, I suspect that you'll see returns that continue to outpace over the next 12-18 months.",0.9000865817070007,0.0154292406514287,0.08448418974876404,positive,0.8846573233604431
99,2012-03-12 02:00:00,JW: CareFusion Corporation (CFN:NYSE) was spun out of Cardinal Health Inc. (CAH:NYSE) three years ago.,0.01850932650268078,0.03360883519053459,0.947881817817688,neutral,-0.015099508687853813
100,2012-03-12 02:00:00,"A year ago the company got a new CEO, Kieran Gallahue, who came from ResMed Inc. (RMD:NYSE).",0.11820537596940994,0.010005911812186241,0.8717886805534363,neutral,0.10819946229457855
101,2012-03-12 02:00:00,"When he was at ResMed he had a very good eye on expense management, taking several hundred basis points out of SG&A over a two-year period.",0.17008286714553833,0.010622789151966572,0.8192943334579468,neutral,0.15946008265018463
102,2012-03-12 02:00:00,"He moved or expanded manufacturing of ResMed products into Singapore, which is more sheltered from foreign exchange movements than was manufacturing in Australia.",0.4320297837257385,0.015860194340348244,0.5521100163459778,neutral,0.41616958379745483
103,2012-03-12 02:00:00,I think he's going to bring this approach to market expansion and expense management to CareFusion.,0.2327543944120407,0.0067039672285318375,0.7605416178703308,neutral,0.22605042159557343
104,2012-03-12 02:00:00,"Management guidance is up, and by the time CareFusion exits fiscal 2014, the company will be showing operating margins of 20%.",0.8947159647941589,0.01666461117565632,0.08861946314573288,positive,0.8780513405799866
105,2012-03-12 02:00:00,"TLSR: Joanne, what are the product lines that will move CareFusion?",0.06105804815888405,0.007291694171726704,0.9316502809524536,neutral,0.05376635491847992
106,2012-03-12 02:00:00,JW: This one is less about product lines and more about blocking and tackling to get that operating margin up.,0.14057618379592896,0.018983952701091766,0.8404399156570435,neutral,0.12159223109483719
107,2012-03-12 02:00:00,The stock will trade as the operating margin moves.,0.033236775547266006,0.014070051722228527,0.9526931643486023,neutral,0.019166722893714905
108,2012-03-12 02:00:00,"JW: ArthroCare Corporation (ARTC:NASDAQ) is a small-cap name, sub-$1 billion.",0.01660342514514923,0.010689259506762028,0.9727072715759277,neutral,0.005914165638387203
109,2012-03-12 02:00:00,The company has moved through a lot of legal issues.,0.03060200624167919,0.48365849256515503,0.485739529132843,neutral,-0.4530564844608307
110,2012-03-12 02:00:00,It has two lawsuits still outstanding that are associated with U.S. Department of Justice inquiries.,0.03297955542802811,0.5530564188957214,0.41396400332450867,negative,-0.5200768709182739
111,2012-03-12 02:00:00,The older one I expect should be resolved in late spring/early summer.,0.02614438347518444,0.01486286148428917,0.9589927792549133,neutral,0.011281521990895271
112,2012-03-12 02:00:00,"The second one is a new one, and so I do not have any timing for that one.",0.015523075126111507,0.045006074011325836,0.9394708871841431,neutral,-0.029482997953891754
113,2012-03-12 02:00:00,The company is in sports medicine and it is part of our consolidation call on the orthopedic market.,0.2140454798936844,0.005537071265280247,0.7804174423217773,neutral,0.20850840210914612
114,2012-03-12 02:00:00,"TLSR: So, it's a takeout candidate.",0.2715774476528168,0.020182078704237938,0.7082404494285583,neutral,0.2513953745365143
115,2012-03-12 02:00:00,Is its low relative strength due to the Justice Department inquiry?,0.027320563793182373,0.39567649364471436,0.5770029425621033,neutral,-0.368355929851532
116,2012-03-12 02:00:00,"TLSR: Assuming the first Justice Department issue is resolved, would another company assume liability of the newer issue and acquire the company, or must both issues be resolved prior to consolidation?",0.014477049931883812,0.016202986240386963,0.9693199396133423,neutral,-0.001725936308503151
117,2012-03-12 02:00:00,JW: I don't have an answer to that.,0.03637314587831497,0.2556063234806061,0.7080205678939819,neutral,-0.2192331850528717
118,2012-03-12 02:00:00,It's a great question though.,0.06589232385158539,0.03582191467285156,0.8982857465744019,neutral,0.030070409178733826
119,2012-03-12 02:00:00,TLSR: Thank you very much.,0.5146979093551636,0.024409718811511993,0.46089234948158264,positive,0.4902881979942322
120,2012-03-12 02:00:00,I've enjoyed this.,0.476799339056015,0.012782801873981953,0.5104178190231323,neutral,0.46401652693748474
121,2012-03-12 02:00:00,"Joanne Wuensch is a research analyst in BMO Capital Markets' Equity Research Group, covering medical technology companies in the cardiology, ophthalmology, orthopaedic and respiratory sectors.",0.02708144299685955,0.007501979824155569,0.9654166102409363,neutral,0.019579462707042694
122,2012-03-12 02:00:00,"Before joining BMO Capital Markets, she was a research analyst with ABN Amro (ING Barings) covering medical products and was a research associate in the medical technology group at UBS Securities.",0.03648184612393379,0.01056946162134409,0.9529486894607544,neutral,0.025912385433912277
123,2012-03-12 02:00:00,"Her career in financial services began at J.P. Morgan, where, among other positions, she was an associate in municipal finance investment banking in the healthcare and higher education group.",0.05183227360248566,0.008323327638208866,0.9398443698883057,neutral,0.043508946895599365
124,2012-03-12 02:00:00,Wuensch joined BMO Capital Markets in 2002.,0.046036940068006516,0.007728416472673416,0.9462347030639648,neutral,0.0383085235953331
125,2012-03-12 02:00:00,1) George Mack of The Life Sciences Report conducted this interview.,0.02136320248246193,0.010997188277542591,0.9676396250724792,neutral,0.010366014204919338
126,2012-03-12 02:00:00,He personally and/or his family own shares of the following companies mentioned in this interview: None.,0.007173165213316679,0.024329790845513344,0.9684970378875732,neutral,-0.017156625166535378
127,2012-03-12 02:00:00,2) The following companies mentioned in the interview are sponsors of The Life Sciences Report: None.,0.0075260549783706665,0.028725899755954742,0.9637480974197388,neutral,-0.021199844777584076
128,2012-03-12 02:00:00,3) Joanne Wuensch: I personally and/or my family own shares of the following companies mentioned in this interview: None.,0.008161980658769608,0.026821918785572052,0.9650161266326904,neutral,-0.018659938126802444
129,2012-03-12 02:00:00,I personally and/or my family am paid by the following companies mentioned in this interview: None.,0.00921571534126997,0.04550207778811455,0.9452821612358093,neutral,-0.036286361515522
130,2012-03-12 02:00:00,I was not paid by Streetwise for participating in this story.,0.025430547073483467,0.19280508160591125,0.7817643284797668,neutral,-0.16737453639507294
131,2012-03-12 02:00:00,Want to read more exclusive Life Science Report interviews like this?,0.04721418768167496,0.014516212046146393,0.9382696151733398,neutral,0.032697975635528564
132,2012-03-12 02:00:00,"Sign up for our free e-newsletter, and you'll learn when new articles have been published.",0.05619412660598755,0.007124368101358414,0.9366815686225891,neutral,0.049069758504629135
133,2012-03-12 02:00:00,Streetwise - The Life Sciences Report is Copyright Â© 2012 by Streetwise Reports LLC.,0.022162219509482384,0.006713896058499813,0.9711238741874695,neutral,0.01544832345098257
134,2012-03-12 02:00:00,All rights are reserved.,0.013616012409329414,0.010146472603082657,0.9762375354766846,neutral,0.0034695398062467575
135,2012-03-12 02:00:00,"Streetwise Reports LLC hereby grants an unrestricted license to use or disseminate this copyrighted material (i) only in whole (and always including this disclaimer), but (ii) never in part.",0.020343922078609467,0.007967857643961906,0.9716882705688477,neutral,0.01237606443464756
136,2012-03-12 02:00:00,"The Life Sciences Report does not render general or specific investment advice and does not endorse or recommend the business, products, services or securities of any industry or company mentioned in this report.",0.010346943512558937,0.015458432957530022,0.9741946458816528,neutral,-0.005111489444971085
137,2012-03-12 02:00:00,"From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles on the site, may have a long or short position in securities mentioned and may make purchases and/or sales of those securities in the open market or otherwise.",0.009586303494870663,0.019300317391753197,0.9711133241653442,neutral,-0.009714013896882534
138,2012-03-12 02:00:00,Streetwise Reports LLC does not guarantee the accuracy or thoroughness of the information reported.,0.014646953903138638,0.03390306979417801,0.951449990272522,neutral,-0.019256114959716797
139,2012-03-12 02:00:00,Streetwise Reports LLC receives a fee from companies that are listed on the home page in the In This Issue section.,0.00978822074830532,0.014373167417943478,0.9758386015892029,neutral,-0.004584946669638157
140,2012-03-12 02:00:00,Their sponsor pages may be considered advertising for the purposes of 18 U.S.C.,0.011596734635531902,0.011748005636036396,0.9766552448272705,neutral,-0.0001512710005044937
141,2012-03-12 02:00:00,1734.,0.04673630744218826,0.023851728066802025,0.9294118881225586,neutral,0.022884579375386238
142,2012-03-12 02:00:00,Participating companies provide the logos used in The Life Sciences Report.,0.018828589469194412,0.007025974337011576,0.9741454720497131,neutral,0.011802615597844124
143,2012-03-12 02:00:00,These logos are trademarks and are the property of the individual companies.,0.0122009152546525,0.01009165495634079,0.9777073860168457,neutral,0.0021092602983117104
144,2012-03-12 02:00:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
